FindTrial
Sign In

Prednisone acetate

DRUG4 trials

Sponsors

Merck Sharp & Dohme LLC, Warrenville Eyecare

Conditions

Evaporative Dry EyeMeibomian Gland DysfunctionMetastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic castration resistant prostate cancerProstatic Neoplasms

Phase 3

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
RecruitingNCT06136650
Merck Sharp & Dohme LLCMetastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Start: 2023-12-18End: 2030-12-02Target: 1314Updated: 2026-03-30
MK-5684-003: A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003)
RecruitingCTIS2023-504899-25-00
Merck Sharp & Dohme LLCMetastatic castration resistant prostate cancer
Start: 2024-04-04Target: 393Updated: 2025-12-04
MK-5684-004: A Phase 3, Randomized, Open-label Study of Opevesostat Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (OMAHA-004)
SuspendedCTIS2023-504957-11-00
Merck Sharp & Dohme LLCMetastatic castration resistant prostate cancer
Start: 2024-04-05Target: 401Updated: 2025-11-13

Phase 4

Dextenza With ILUX for Treatment of MGD
CompletedNCT04658927
Warrenville EyecareEvaporative Dry Eye, Meibomian Gland Dysfunction
Start: 2021-01-04End: 2021-05-30Updated: 2022-07-27

Related Papers

Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designs.
2026-02-23
Phase 3 OMAHA-004 study of CYP11A1 inhibitor opevesostat versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after 1 prior NHA.
Journal of Clinical Oncology2025-02-101 citations
CYP11A1 inhibitor MK-5684 versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after 1 prior NHA: Phase 3 MK-5684-004 study.
Journal of Clinical Oncology2024-06-01